Jordan, B., Jahn, F., Beckmann, J., Unverzagt, S., Muller-Tidow, C., & Jordan, K. (2016). Calcium and magnesium infusions for the prevention of oxaliplatin-induced peripheral neurotoxicity: A systematic review. Oncology, 90, 299–306.

DOI Link

Purpose

STUDY PURPOSE: To summarize the evidence regarding the effects of calcium and magnesium infusion to prevent peripheral neuropathy associated with oxaliplatin

TYPE OF STUDY: Meta-analysis and systematic review

Search Strategy

DATABASES USED: MEDLINE, Cochrane Collaboration, conference proceedings from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) from 1990–2016

INCLUSION CRITERIA: Human trials

EXCLUSION CRITERIA: None specified

Literature Evaluated

TOTAL REFERENCES RETRIEVED: 846

EVALUATION METHOD AND COMMENTS ON LITERATURE USED: Not described

Sample Characteristics

FINAL NUMBER STUDIES INCLUDED = 5
TOTAL PATIENTS INCLUDED IN REVIEW = 694
SAMPLE RANGE ACROSS STUDIES: 27–353
KEY SAMPLE CHARACTERISTICS: All were on FOLFOX regimens.

Phase of Care and Clinical Applications

PHASE OF CARE: Active antitumor treatment

Results

Across four studies (640 patients), the relative risk of grade 2 or higher chemotherapy-induced peripheral neuropathy was 0.81; however, the z test for overall effect showed no statistical significance. The largest trial showed no difference between groups.

Conclusions

The findings did not show any benefit of calcium and magnesium infusions for the prevention of oxaliplatin-induced peripheral neuropathy.

Limitations

Limited number of studies included
No quality evaluation
Low sample sizes
Two of the five studies had very low sample sizes.

Nursing Implications

The findings do not support the use of calcium and magnesium infusions to prevent chemotherapy-induced peripheral neuropathy.

Legacy ID

6498